Reviewer’s report

Title: Real Life Patterns of Care and Progression Free Survival in Metastatic Renal Cell Carcinoma Patients: Retrospective Analysis of Cross-Sectional Data

Version: 2 Date: 08 Jan 2018

Reviewer: Jinsoo Chung

Reviewer's report:

The manuscript was well prepared and answered relevantly to all the reviewers' questions. Some minor information should be added for the better understanding of the manuscript.

1. The flowchart of patient selection in the supplementary showed that those enrolled patients had a history of previous immunochemotherapy. These should be mentioned in the results section as well as in the methods section that which immuno or chemotherapeutic agents were used.

This information is important to validate the PFS of the enrolled patients treated with first line therapy.

2. The authors wanted to show the prognostic outcome of PFS in first-line targeted therapy in real setting world. However, the authors showed in the table 1 that the second and third-line targeted therapy were shown. I would like to ask you to describe the rationale for the second and third-line targeted therapy in France, What is the rationale for the National Insurance coverage? What factors affected the doctors to decide to choose which targeted agents for the mRCC patients? The criteria of choosing the target agents should be described in the methods section.

3. As the authors showed the second and third-line targeted therapy, what was the overall survival of the enrolled patients in this study?

4. Try to describe the PFS according to the previous therapeutic history. For example, were there any differences in PFS between previous chemotherapeutic patients and non-treated patients.

The authors mentioned in the early Methods section that all the patients were naive mRCC patients, whereas in the flow chart of inclusion criteria of supplementary files, those enrolled patients had a previous history of chemotherapy.

5. How did the authors define the metachronous and synchronous mRCC? The authors mentioned that 390 patients were diagnosed metachronous mRCC with a mean interval
between diagnosis 141 and metastasis was 41 months. Usually, the synchronous metastasis was defined a cut-off point of 3 months from surgery in kidney cancer.

**Are the methods appropriate and well described?**
If not, please specify what is required in your comments to the authors.

No

**Does the work include the necessary controls?**
If not, please specify which controls are required in your comments to the authors.

No

**Are the conclusions drawn adequately supported by the data shown?**
If not, please explain in your comments to the authors.

Yes

**Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?**
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

I am able to assess the statistics

**Quality of written English**
Please indicate the quality of language in the manuscript:

Acceptable

**Declaration of competing interests**
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?
5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

'I declare that I have no competing interests' below

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal